Novanta (US:NOVT)2026-02-24 14:02Financial Data and Key Metrics Changes - Novanta reported record revenue in Q4 2025 with a 9% reported growth, 2% organic growth, and 4% sequential growth [5] - Full-year revenue reached $981 million, marking the largest year in the company's history, with full-year bookings growing by 14% [5] - Adjusted EBITDA grew by 17% year-over-year, and Adjusted Diluted EPS increased by 20% [6][23] - Non-GAAP adjusted gross profit for Q4 was $118 million, with a 45.5% adjusted gross margin, down from 47% in Q4 2024 [21] - Operating cash flow in Q4 was $9 million, significantly lower than $62 million in Q4 2024, impacted by regional manufacturing dynamics [24] Business Line Data and Key Metrics Changes - New product revenue grew over 60% for the full year, with over 80% growth in Q4 [6][20] - Automation Enabling Technologies segment revenue grew by 2% year-over-year, with bookings up 33% [27] - Precision Manufacturing Business saw a 3% revenue decline year-over-year in Q4 but had an 8% sequential growth [27] - Medical Solutions segment revenue grew by 16% year-over-year in Q4, with advanced surgery business growing 15% [30] Market Data and Key Metrics Changes - Sales in medical end markets represented 53% of total sales, while advanced industrial markets accounted for 47% [20] - Medical consumable sales grew at a strong double-digit rate, representing 15% of total company sales [20] - The Robotics & Automation business is expected to see high single-digit growth in 2026, driven by AI-driven tailwinds [12][13] Company Strategy and Development Direction - Novanta's long-term growth strategy focuses on high-growth end markets such as AI-driven Robotics & Automation, minimally invasive surgery, and precision medicine [8] - The company aims to expand its business mix and technology leadership in medical technologies and embedded software [9] - Acquisitions are a key growth strategy, with a pipeline focused on mid to larger opportunities in medical technologies and consumables [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit organic growth in 2026, supported by strong bookings and new product launches [10][18] - The company anticipates a significant inventory drawdown and strong cash rebound as regional manufacturing initiatives are completed [24] - Management highlighted the importance of customer relationships and the need for capable suppliers in the medical technology space [84] Other Important Information - The company ended Q4 with gross debt of $260 million and a net cash position for the first time in over a decade [25] - Novanta's acquisition capacity stands at nearly $1.5 billion, with a robust acquisition pipeline [42] Q&A Session Summary Question: Can you elaborate on the increase in bookings in the Automation Enabling Technologies segment? - Management noted broad-based growth across all businesses, with strong momentum in Robotics & Automation driven by precision robotics and semiconductor capital equipment [46][47] Question: What is the revenue expectation for the industrial robotics order announced previously? - Management indicated that revenue from the order will ramp modestly this year, with expectations for sequential growth [54] Question: How does the company reconcile strong bookings momentum with EPS growth expectations? - Management explained that the EPS growth is impacted by the recent fundraise and an all-employee equity grant, but organic growth remains strong [62][63] Question: Can you provide insights on the GPU boards opportunity? - Management highlighted that the company is the leader in drilling for GPU boards, with increasing demand from new end users in the AI space [67][68] Question: Is the positive book-to-bill across all business units? - Management confirmed that all four business units had a positive book-to-bill ratio, indicating strong momentum and backlog growth [71][72]